Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis
Haokun Tian, Changsen Yang, Tiangang Song, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 19

Showing 19 citing articles:

Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections
Mohammed Nooruzzaman, Katherine Johnson, Ruchi Rani, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Irfan Ullah, Fanny Escudié, Ivan Scandale, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109049-109049
Open Access | Times Cited: 6
Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis
Behnam Amani, Bahman Amani
Reviews in Medical Virology (2024) Vol. 34, Iss. 4
Closed Access | Times Cited: 5
Safety and Efficacy of Camostat Mesylate for Covid-19: a systematic review and Meta-analysis of Randomized controlled trials
Ubaid Khan, Muhammad Mubariz, Yehya Khlidj, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Nirmatrelvir/ritonavir prescription and the risk of hospitalization and death in COVID-19 outpatients
Héctor Raúl Vargas-Sánchez, Juan Carlos Tomás-López, E Guzmán-Medina, et al.
Medicina de Familia SEMERGEN (2025) Vol. 51, Iss. 6, pp. 102461-102461
Closed Access
Safety and Effectiveness of Nirmatrelvir-Ritonavir in Patients With Advanced Kidney Dysfunction and COVID-19
Marimar Contreras Nieves, Shuchi Anand, I‐Chun Thomas, et al.
American Journal of Kidney Diseases (2025)
Closed Access
Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis
Bahman Amani, Behnam Amani
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0298772-e0298772
Open Access | Times Cited: 2
Low Prevalence of Nirmatrelvir-Ritonavir Resistance-Associated Mutations in SARS-CoV-2 Lineages From Botswana
Wonderful T. Choga, Ontlametse T. Bareng, Natasha O. Moraka, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 7
Open Access | Times Cited: 2
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis
Behnam Amani, Bahman Amani
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 7, pp. 547-555
Closed Access | Times Cited: 1
The Dual-Targeted Fusion Inhibitor Clofazimine Binds to the S2 Segment of the SARS-CoV-2 Spike Protein
Matthew R. Freidel, Pratiti A. Vakhariya, Shalinder K. Sardarni, et al.
(2024)
Open Access | Times Cited: 1
The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19
Katie Bechman, Amelia Green, Mark Russell, et al.
Journal of Infection (2024) Vol. 89, Iss. 3, pp. 106227-106227
Open Access | Times Cited: 1
Coronavirus Disease 2019 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: A Prospective Cohort Study
Jacqueline K. Kueper, Kalyani Kottilil, Giorgio Quer, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
The Dual-Targeted Fusion Inhibitor Clofazimine Binds to the S2 Segment of the SARS-CoV-2 Spike Protein
Matthew R. Freidel, Pratiti A. Vakhariya, Shalinder K. Sardarni, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 640-640
Open Access
Association of TLR4 gene rs4986790 and rs4986791 polymorphisms with asthma susceptibility: meta-analysis and trial sequential analysis
Nan Guo, Haokun Tian, Tiangang Song, et al.
Annals of Saudi Medicine (2024) Vol. 44, Iss. 3, pp. 183-194
Open Access
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections
Mohammed Nooruzzaman, Katherine Johnson, Ruchi Rani, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Identification and evaluation of candidate COVID-19 critical genes and medicinal drugs related to plasma cells
Zhe Liu, Olutomilayo Olayemi Petinrin, Nanjun Chen, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access
The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19
Katie Bechman, Amelia Green, Mark Russell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Association between UCP2 gene 3’UTR I/D and A55V polymorphisms and neural tube defects susceptibility: systematic review, meta-analysis, and trial sequential analysis
Haokun Tian, Zhen Guan, Li Shen, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access
Perfil de seguridad de Paxlovid® contra SARS-CoV2 en pacientes de un hospital en México
Belem Arieth Chan Canche, Abraham Arcos-Díaz, Kyra Angélica Argáez-Ojeda, et al.
Ars Pharmaceutica (Internet) (2024) Vol. 65, Iss. 4, pp. 295-306
Open Access
Page 1

Scroll to top